Morbidity and Mortality in Cardiovascular Disorders: Impact of Reduced Heart Rate

Abstract

References

1. Levine HJ. Heart rate and life expectancy. J Am Coll Cardiol 30:1104-1104, 1997

2. Spector WS. Handbook of Biological Data, WB Saunders, Philadelphia, 1956, p 41-41

3. White PD , Jenkins JL , Benedict FG. The electrocardiogram of the elephant. Am Heart J 16:744-750, 1938

4. DiFrancesco D , Ferroni A , Mazzanti M , Tromba C. Properties of the hyperpolarizing-activated current (If) in cells isolated from rabbit sinoatrial node. J Physiology 377:61-61, 1986

5. Cosigner W , Lillie C. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3[[2 - (3,4-dimethoxyphenyl) ethyl]methylimino] propyl] - 2H-3-benzapin-2-on hydrochloride, a new “specific bradycardic agent”. Eur J Pharmacol 104:9-15, 1984

6. Lillie C , Singh BN. Sinus Node Inhibitors. In Singh BN , Dzau VJ , Vanhoutte PM , Woosley RL (eds). Cardiovascular Pharmacology and Therapeutics. Churchill Livingstone, New York, 1994, pp 203-216

7. Beere P , Glagov S , Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226:180-182, 1984

8. Kaplan J , Manuck S , Adams M. Propranolol inhibits coronary atherosclerosis in behaviorally predisposed monkeys fed with atherogenic diet. Circulation 761:1364-1372, 1987.

9. Perski A , Hamsten A , Lindlvall K , Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 116:1369-1373, 1988

10.

10. Perski A , Ollson G , Landau C , et al. Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 123:6091-6099, 1992

11.

11. Boraso A. Why is reduced heart rate beneficial. Dialogues in Cardiovascular Medicine 6:19-24, 2001

12.

12. Schmidt-Nielsen K. Animal Physiology: Adaptation and Environment. New York: Cambridge University Press, 1975, p 133-133

13.

13. Palatino P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality. Drugs 57:713-722, 1999

14.

14. Dyer A , Perski V , Stamler J , Stamler J , Paul O , Shekelle RB , et al. Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies. Am J Epidemiol 12:736-749, 1980

15.

15. Wilhelmsen L , Berglund G , Elmfeldt D , Elmfeldt D , Tibblin G , Wedel H , et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J 7:279-288, 1986

16.

16. Kannel W , Wilson P , Blaire S. Epidemiologic assessment of the role of physical activity and fitness in development of cardiovascular disease. The Framingham Study. Am Heart J 109:876-885, 1985

17.

17. Kannel W , Kannel C , Paffenbarger R , Cupples A. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 113:1489-1494, 1987

18.

18. Gillum R. The epidemiology of resting heart rate in a national sample of men and women: Association with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors. Am Heart J 116:163-174, 1988

19.

19. Gillum R , Makuc D , Feldman J. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic followup study. Am Heart J 121:172-177, 1991

20.

20. Gillman M , Kannel W , Belanger A , D'Agostino R. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 125:1148-1154, 1993

21.

21. Castelli WP , Levy D , Wilson PWF , Kannel W. Sudden death: The view from Framingham. In Kostis JB , Sanders M (eds). The Prevention of Sudden Death. E Wiley-Liss, New York, 1990, pp 1-8

22.

22. Goldberg R , Larson M , Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: The Framingham study. Arch Intern Med 156:505-509, 1996

23.

23. Habib G. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Therapeut 19 (suppl A):39-55, 1997

24.

24. Singh BN. The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina. Can J Cardiol 15 (suppl A): 15A-121A, 1999

25.

25. Habib GB. Reappraisal of heart rate as a risk factor in the general population. Eur Heart J l(suppl H):H2-H2, 1999

26.

26. Habib GB.

Is heart rate a risk factor in the general population?

Dialogues in Cardiovascular Medicine 6:25-31, 2001

27.

27. Purcell H.

Is heart rate a prognostic factor for cardiovascular disease?

Dialogues in Cardiovascular Medicine 6:32-36, 2001

28.

28. Singh BN. Heart rate reduction and morbidity and mortality in cardiovascular disorders. In BN Singh , PM Vanhoutte (eds). Heart Rate Reduction by Specific Blocking Compounds in the Control of Myocardial Ischemia and Prolongation of Survival. Lippincott, Williams, and Wilkins, London, 2001 (in press)

29.

29. Shaper AG , Wannamethee G , Macfarlane PW , Walker M. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 70:49-55, 1993

30.

30. Mensink GB , Hoffmeister H. The relationship between resting heart rate and all-cause cardiovascular and cancer mortality. Eur Heart J 18:1404-1410, 1997

31.

31. Greenland P , Daviglus ML , Dyer AR , et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: The Chicago Heart Association Detection Project in Industry. Am J Epidemiol 149:853-862, 1999

32.

32. Benetos A , Rucnichi A , Thomas F , Safar M , Guize L. Influence of heart rate on mortality in a French population: Role of age, gender and blood pressure. Hypertension 33:44-52, 1999

33.

33. Kristal-Boneh E , Silber H , Harari G , P Froom . The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight-year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 21116-21124, 2000

34.

34. Green M , Peled I. Prevalence and control of hypertension in a large cohort of occupationally-active Israelis examined during 1985-1987. The CORDIS Study. Int J Epidemiol 21:674-682, 1992

35.

35. Reunanen A , Karjalainen J , Ristola P , Heliovaara M , Knekt P , Aromaa A. Heart rate and mortality. J Intern Med 247:231-239, 2000

36.

36. Purcell H. Heart as a therapeutic target in ischemic heart disease. Eur Heart J l(suppl H):H58-H63, 1999

37.

37. Palatini P. Need for revision of the normal limits of resting heart rate. Hypertension 33:622-625, 1999

38.

38. Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens 17 (suppl 3):S3-S10, 1999

39.

39. Kim JR , Klefe CI , et al. Heart rate and subsequent blood pressure in young adults. The CARDIA Study. Hypertension 33:640-646, 1999

40.

40. Wannamethee G , Shaper AG. The association between heart rate and blood pressure, blood lipids and other cardiovascular risk factors. J Cardiovasc Risk 1:223-230, 1994

41.

41. Fogari R , Zoppi A , Marasi et al. The epidemiology of resting heart rate in a male working population: Association with blood pressure, age, smoking habits and other cardiovascular risk factors. J Cardiovasc Risk 4:209-213, 1997

42.

42. Rastenyte D , Tuomilehto J , Moltchanov V , Lindstrom J , Pietinen P , Nissinen A. Association between salt intake, heart rate, and blood pressure. J Hum Hypertens 11:57-62, 1997

43.

43. Morcet JF , Safar M , Thomas F , Guize L , Benetos A. Association between heart rate and other risk factors in a large French population. J Hyperten 17 (suppl 12): 1670-1676, 1999

44.

44. Farinaro E , Stranges S , Guglielmucci G , et al. Heart rate as a risk factor in hypertensive individuals. The Italian TensioPulse Study. Nutr Metab Cardiovasc 9:196-202, 1999

45.

45. Ferrieres J , Ruidavets JB. Association between resting heart rate and hypertension treatment in a general population. Am J Hypertens 12:628-631, 1999

46.

46. Zhang J , Kesteloot H. Anthropometric, lifestyle, and metabolic determinants of resting heart rate. A population study. Eur Heart J 20:103-110, 1999

47.

47. Aronow WS , Ahn C , et al. Association of average heart rate on 24-hour ambulatory electrocardiograms with the incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 78:1175-1176, 1996

48.

48. Palatini P , Casiglia E , Julius S , Pesina AC. High heart rate. A risk factor for cardiovascular death in elderly men. Arch Int Med 159:585-592, 1999

49.

49. Hjalmarson A , Gilpin E , Kjekshus J , et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65:547-553, 1990

50.

50. Gundersen T , Grottum P , Pedersen T , Kjekshus J , for the Norwegian Timolol Multi-center Study Group . Effect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at rest. Am J Cardiol 58:20-24, 1986

51.

51. Kendall MJ , Lynch KP , Hjalmarson A , Kjekshus J. Betablockers and sudden cardiac death. Annals of Internal Medicine 123(5):358-367, 1995

52.

52. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80(9B):35J-39J, 1997

53.

53. Beta-blocker Heart Attack Trial Research Group : A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 247(12):1707-1714, 1982

54.

54. Yusuf S , Peto R , Lewis J , Sleight P. Beta-blockade during myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis 27:335-371, 1985

55.

55. Reiter MJ. Antiarrhythmic impact of anti-ischemic, antifailure and other cardiovascular strategies. Card Electrophysiological Rev 4:194-205, 2000

56.

56. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF). Lancet 353:2001-2007, 1999

57.

57. Packer M. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog Cardiovasc Dis 41 (suppl 1):39-52, 1998

58.

58. Packer M , Coats , Fowler , Kats , Krum , Mohasco , et al. for The Carvedilol Prospective Randomized Cumulative Survival Study Group. N Engl J Med 344:1651-1658, 2001

59.

59. Bristow MR. B-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000

60.

60. CIBIS II Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial. Lancet 353:9-13, 1999

61.

61. The Beta-blocker Evaluation of Survival Trial Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001

62.

62. Kjekshus J. Comments-beta-blockers: Heart rate reduction a mechanism of benefit. Eur Heart J 6:29-30, 1985

63.

63. Kjekshus J. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57:43F-49F, 1986

64.

64. Julian DG , Prescott RJ , Jackson FS , Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1142-1147, 1982

65.

65. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Ann Rev Physiology 55:451-467, 1993

66.

66. Singh BN , Vanhoutte PM. Specific heart lowering therapy: Prospects for controlling myocardial ischemia and prolonging survival. 2000 (in press)

67.

67. Quyyumi AA , Panza JA , Diodat JG , Lakatos E , Epstein SE. Circadian variation in ischemic threshold: A mechanism underlying the circadian variation in ischemic events. Circulation 87:808-814, 1993

68.

68. Reiter MJ , Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82 (4A):91-91, 1998

69.

69. Singh BN. Advantages of beta-blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention of myocardial infarction. Am J Cardiol 66:9C-20C, 1990

70.

70. Singh BN. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of cardiac rhythm. Am J Cardiol 81:3D-13D, 1998

71.

71. Detry JM , Seller P , Pennaforte S , et al. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Pharmacol 34:279-288, 1994

72.

72. Mody FV , Singh BN , Mohiuddin IH , et al. Trimetazidineinduced enhancement of myocardial glucose utilization in normal and ischaemic myocardial tissue: An evaluation by positron emission tomography. Am J Cardiol 82:42K-49K, 1998

73.

73. Cocco G , Rousseau MF , Bouvy T , et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with a beta-blocker or diltiazem. J Cardiovasc Pharmacol 20:131-132, 1992

74.

74. Pepine CJ , Wolff AA. A controlled trial with a novel antiischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Am J Cardiol 84(1):46-50, 1999

75.

75. Cosigner W , Lillie C. Falipamil (AQ-A 39) and UL-FS 49. Cardiovasc Drug Rev 6:35-43, 1988

76.

76. Krayer O Veratramine, an antagonist to the caridoaccelerator action of epinephrine. Proc Soc Exp Biol Med 70:631-638, 1949

77.

77. Krumpf G , Winkler M , Schneider W , Raberger G. Comparison of the hemodynamic effects of the selective bradycardic agent UL-FS 49 with those of propranolol during treadmill exercise in dogs. Br J Pharmacol 94:55-62, 1988

78.

78. Singh BN , Vaughan Williams EM. A fourth class of antiarrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 6:109-119, 1972

79.

79. Thollon C , Cambarrat C , Vian J , Prost JF , Peglion JL , Vilaine JP. Electrophysiological effects of S 16527, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: Comparison with UL-FS 49. Br J Pharmacol 112:37-42, 1994

80.

80. Goethals M , Raes A , Van Bogaert PP. Use-dependent block of the pacemaker current I, of the rabbit sinoatrial node cellas by zatebradine (UL-FR 49). Circulation 88:2389-2401, 1993

81.

81. Gilfrich HJ , Oberhoffer M , Witzke J. Comparison of AQA 39 and propranolol and placebo anin ischemic heart disease. Eur Heart J 8 (suppl L):147-155, 1987

82.

82. Indolfi C , Guth BD , Miura T , Miyazaki S , Schulz R , Ross J. Mechanism of improved regional myocardial dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation 80:983-993, 1989

83.

83. Thollon C , Bidouard J-P , Cambarrat C , Lesage L , Reure H et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 339:43-51, 1997

84.

84. Bois PR Bescond J , Renaudon B , Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Brit J Pharmacol 118:1051-1057, 1996